ArticleAmerican journal of ophthalmology case reports2021
Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases.
Article in American journal of ophthalmology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI.Frontiers in medicine · 2026Review
- Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review.Cureus · 2023Review
- Teprotumumab in thyroid eye disease: wonder drug or great divider?European thyroid journal · 2023Article
- Dysthyroid optic neuropathy: emerging treatment strategies.Journal of endocrinological investigation · 2023Review
- Thyroid Eye Disease.Life (Basel, Switzerland) · 2022Review
- Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2022Review
- Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.Indian journal of ophthalmology · 2022Review
- Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy.Current neurology and neuroscience reports · 2022Review
- Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.Therapeutics and clinical risk management · 2021Review
- Updates on the understanding and management of thyroid eye disease.Therapeutic advances in ophthalmologyReview
- Thyroid eye disease: From pathogenesis to targeted therapies.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report two cases of thyroid eye disease (TED) associated compressive optic neuropathy (CON) that resolved after treatment with teprotumumab. OBSERVATION: Two patients presented with active TED resulting in mild CON with the typical corresponding visual field (VF) defects. Both patients were initiated on intravenous (IV) corticosteroid therapy but despite treatment had persistent VF defects. Both patients were then treated with teprotumumab and demonstrated marked clinical improvement and complete resolution of TED-CON VF defects early in their infusion course. CONCLUSIONS AND IMPORTANCE: These cases suggest that teprotumumab can be a rapid and effective treatment for TED-CON, and raises the question of whether it may be superior to IV corticosteroid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.